Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.1Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with strong clinical trial results, better-than-expected first-quarter revenue, and robust demand for RenovoCath. However, there were some increases in operating expenses and limited international market presence.Company Guidance
During the RenovoRx Q1 2025 financial call, the company highlighted several key metrics and guidance for the future. RenovoRx reported its first revenue of approximately $200,000 from the sale of its FDA-cleared RenovoCath device, surpassing initial expectations. This revenue marks the beginning of commercial sales for the device, which is part of a broader strategy to expand its market presence, targeting a potential U.S. sales opportunity of $400 million annually. The ongoing Phase 3 TIGeR-PaC clinical trial demonstrated promising results, with patients showing a median overall survival of 16 months using the targeted therapy, compared to 10 months with standard chemotherapy, and a significant 65% reduction in adverse events. Research and development expenses increased to $1.7 million from $1.3 million in Q1 2024, driven by enhanced employee compensation and manufacturing costs, while selling, general, and administrative expenses rose to $1.6 million from $1.2 million. The company has $14.6 million in cash, which is expected to fund ongoing clinical trials and commercial scale-up. Looking forward, RenovoRx anticipates continued revenue growth and is exploring strategic partnerships to enhance market penetration.Encouraging Clinical Trial Results
The ongoing Phase 3 TIGeR-PaC clinical trial showed that patients experienced median overall survival of 16 months with the targeted approach, compared to 10 months with standard chemotherapy. Additionally, there was a 65% reduction in adverse events such as nausea and fatigue.
First Quarter Revenue Exceeds Expectations
RenovoRx reported approximately $200,000 in revenue from the RenovoCath device, exceeding initial expectations and marking the company's first quarter of commercial sales.
Strong Market Interest and Demand
There is strong organic demand for RenovoCath, with more than 10 new medical institutions initiating purchase orders and repeat orders from initial customers.
New U.S. Patent Issued
RenovoRx announced the issuance of a new U.S. patent for their TAMP therapy platform, further enhancing their intellectual property portfolio.
Financial Stability
The company has $14.6 million in cash, expected to fully fund the RenovoCath scale-up and the Phase 3 TIGeR-PaC clinical trial.
---
RNXT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RNXT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $1.11 | ― | ― |
Apr 01, 2025 | $0.99 | $0.96 | -3.03% |
Nov 14, 2024 | $1.09 | $1.09 | 0.00% |
Aug 14, 2024 | $1.16 | $1.12 | -3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does RenovoRx (RNXT) report earnings?
RenovoRx (RNXT) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is RenovoRx (RNXT) earnings time?
RenovoRx (RNXT) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RNXT EPS forecast?
RNXT EPS forecast for the fiscal quarter 2025 (Q2) is -0.07.
---